Novartis Ceritinib India Case: Court Rebuke Amid Wait For Patent Decision
Executive Summary
An Indian court has frowned upon Novartis and opponent Natco for seemingly delaying proceedings before the Controller General of Patents in a case concerning the Swiss firm’s anticancer ceritinib. The patent office wasn’t spared either, with the court asking the Controller to ensure that once orders are reserved, a time period is prescribed for delivering the decision.
You may also be interested in...
Fresh Twist: India Stays Revocation Order On Novartis Ceritinib Patent
Appellate board stays previous order that rescinded the patent on ceritinib in India, giving Novartis the upper hand for now. The spotlight is now on procedural aspects and additional evidence/submission by challenger Natco and rebuttal by the Swiss multinational.
Shadow On Novartis' Ceritinib In India After Patent Is Revoked
A patent on Novartis’ ceritinib has been rescinded in India, giving challenger Natco the upper hand, though the Swiss multinational has filed an appeal and hopes to have the patent reinstated.
Shadow On Novartis' Ceritinib In India After Patent Revoked
A patent on Novartis’ceritinib has been rescinded in India, giving challenger Natco the upper hand, though the Swiss multinational has filed an appeal and hopes to have the patent reinstated.